For authors: extract your paper's claims, reported results, and stated limitations for transparent review and citation.Know what the science actually supports before you trust the answer.
Press Enter ↵ to extract claims
Explore by Goal
"Mood reflects the biology of the brain. How you feel is affected by the chemicals in the brain, and these are the same chemicals that form the basis of mood-altering drugs."
- Liz Miller
Quick Explanation
Copied
Timothy G. Dinan (scientific-strength snapshot): The author’s portfolio (per the works supplied here) strongly emphasizes gut–brain axis mechanisms—especially microbiome ↔ immune ↔ tryptophan/monoamine signaling—with a clear pattern of multi-omics + hypothesis-driven animal work, alongside human-focused synthesis.
Long Explanation
Author Review (Science Strength): Timothy G. Dinan
Evidence basis used here: only the paper-level raw research excerpts you provided (plus their DOIs/links). Any statements about broader career metrics are intentionally constrained to avoid uncited OpenAlex-number claims.
Visuals (what the supplied studies show)
Figure 1 — Immune modulation after chronic Bifidobacterium infantis (rat)
Data provenance: Cytokines measured after immune stimulation/assays in the rat study excerpted by DOI 10.1016/j.jpsychires.2008.03.009 (reported means, SEs, and p-values in your extract).
Your excerpt provides pathway-level conclusions (not a single numeric table for plotting). To stay rigorous (no invented data), this figure is a mechanism schematic constrained to what your text explicitly states.
Scientific strength assessment (mechanistic focus, not PR)
The probiotic rat study directly measures immune cytokines plus tryptophan/kynurenine metabolites and brain monoamine-related readouts, enabling a mechanistic “chain” rather than isolated markers (but see limitations under rigor).
The 2026 Nature Communications mouse multi-omics excerpt explicitly frames “gut-brain-metabolome axis” as the mechanistic bridge, incorporating microbiota profiling and hypothalamic transcriptomics/metabolomics together with behavioral endpoints.
2) Evidence strength vs. mechanistic overreach (what is supported vs. not)
Supported: In the B. infantis study, immune cytokine attenuation is directly reported alongside tryptophan/KYN metabolite shifts.
Not fully supported (for “behavioral antidepressant” claim): The same study reports no effect on forced swim test behavior (despite biochemical changes). That weakens inference from “immune/metabolic modulation” to “antidepressant-like behavioral efficacy.”
Supported but still cautious: The 2026 multi-omics mouse study supports enduring behavioral and hypothalamic endpoint restoration with sex-dependent marker normalization, but translational generalization to humans remains limited by species and model constraints.
3) Human-relevance style: reviews vs. primary evidence
Some of the included works are reviews (e.g., gut–brain axis in health/disease; HPA axis function in schizophrenia; microbiome in neurological disorders), which are valuable for synthesis but inherently less evidentially discriminative than direct primary experiments.
The Nature Reviews Neuroscience review on mind-altering microorganisms explicitly synthesizes gut microbiota effects on brain and behavior.
The HPA-axis schizophrenia systematic review summarizes cortisol evidence across many studies and reports heterogeneity and limitations that prevent a meta-analysis.
4) Rigor & bias checks (from the supplied excerpts)
Pre-registration / multiple analyses: The 2026 study excerpt mentions pre-registration, but also notes that some pathways were nominally significant without FDR significance—this is a red flag for selective pathway emphasis if not carefully corrected.
Confounding interpretability: The 2026 excerpt states an inability to distinguish lactation vs post-weaning exposure effects and that life-long interventions complicate prevention vs reversal interpretation.
Model limitations: In the B. infantis study, the forced swim test yielded no behavioral antidepressant-like effect despite neurochemical changes, a potential example of “mechanism without behavioral translation” within that model.
What would most likely disprove/reshape these conclusions?
For the 2026 “gut-brain-metabolome axis” framing: finding that microbiota-independent routes (or direct metabolite administration) fail to replicate the endpoint restoration, or that microbiome changes occur without hypothalamic/behavior restoration.
For the B. infantis mechanistic chain: demonstrating that cytokine and tryptophan/KYN shifts occur without any neurochemical/behavioral downstream consequences, or that the same biochemical shifts can be induced without microbiota manipulation.
Buttons for deeper BGPT queries
Feedback:
Updated: April 07, 2026
BGPT Author Review
Scientific Quality
80%
High mechanistic focus on gut–brain axis biology with multi-domain measurements (immune cytokines + tryptophan/KYN metabolites + brain readouts; and multi-omics gut→hypothalamus→behavior). Strength: coherent mechanistic chains and explicit sex- and pathway-dependent interpretations. Rigor caveats from the supplied excerpts: some pathway-level findings may be only nominal without FDR; interpretability limitations (timing confounds like lactation vs post-weaning; continuous intervention complicates prevention vs reversal); and at least one study shows biochemical shifts without corresponding behavioral change in the forced swim test, limiting claims of antidepressant-like behavioral efficacy in that paradigm.
Communication Quality
70%
Communication appears structured around mechanistic narratives and biological endpoints (behavior + neurobiology + omics). However, the provided excerpts also include instances where mechanistic framing may outpace behavioral outcomes (e.g., biochemical changes without FST effect), which can reduce clarity/strictness about what is actually demonstrated versus inferred.
Author Novelty
70%
Moderately novel in combining microbiota-targeted interventions with sex-specific, mechanism-linked multi-omics and circuit-relevant hypothalamic markers. Not a brand-new domain overall (gut–brain axis is established), but the specific integration and developmental programming framing is meaningfully progressive.
Scientific Rigor
70%
Rigor is strengthened by multi-omics, explicit endpoint integration, and (in the 2026 excerpt) mention of pre-registration. Rigor is reduced by residual multiple-testing interpretation (nominal significance without FDR), key design limitations affecting causal timing, and model constraints (animal paradigm generalizability; at least one behavioral null result constraining mechanistic-to-behavior inference).
None—author-review question; no provided omics raw tables to algorithmically re-analyze in a code-first way from the excerpted inputs.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A “single universal antidepressant pathway” from probiotic exposure is now less plausible for these excerpts because B. infantis altered immune/metabolite markers without changing forced swim behavior, implying task- and circuit-dependent mediation.
A simplistic “probiotic always improves behavior” strongman hypothesis is weakened by the reported mismatch between biochemical/neurochemical readouts and the lack of FST behavioral change, indicating that biochemical modulation alone may not guarantee behavioral antidepressant-like outcomes.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Discussion